Indoco Remedies Limited (BOM:532612)

India flag India · Delayed Price · Currency is INR
202.35
-3.10 (-1.51%)
At close: Feb 13, 2026
Market Cap18.68B -21.7%
Revenue (ttm)17.60B +2.1%
Net Income-1.14B
EPS-11.75
Shares Outn/a
PE Ration/a
Forward PE71.66
Dividend0.20 (0.10%)
Ex-Dividend DateSep 4, 2025
Volume838
Average Volume3,555
Open200.35
Previous Close205.45
Day's Range200.35 - 206.90
52-Week Range190.00 - 348.10
Betan/a
RSI39.55
Earnings DateFeb 3, 2026

About Indoco Remedies

Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally. It offers products for gastrointestinal, anti-infectives, respiratory, stomatological, vitamins/minerals/nutrients, urological, ophthal/ontological, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological therapeutic areas. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; antibioti... [Read more]

Industry Pharmaceutical Preparations
Founded 1945
Employees 6,000
Stock Exchange Bombay Stock Exchange
Ticker Symbol 532612
Full Company Profile

Financial Performance

Financial Statements

News

Q3 2026 Indoco Remedies Ltd Earnings Call Transcript

Q3 2026 Indoco Remedies Ltd Earnings Call Transcript

10 days ago - GuruFocus

Indoco Remedies Q3 Results: Revenue rises 8.5% YoY to Rs 445.4 crore, net loss at Rs 29.8 crore

Indoco Remedies reported its Q3 financial results, showing steady growth in revenue and operating profitability on a year-on-year basis, while...

12 days ago - Business Upturn

Indoco Remedies Ltd (BOM:532612) Q2 2026 Earnings Call Highlights: Revenue Growth and Strategic ...

Indoco Remedies Ltd (BOM:532612) Q2 2026 Earnings Call Highlights: Revenue Growth and Strategic Challenges

3 months ago - GuruFocus

Q2 2026 Indoco Remedies Ltd Earnings Call Transcript

Q2 2026 Indoco Remedies Ltd Earnings Call Transcript

3 months ago - GuruFocus

Indoco Remedies’ Patalganga API facility clears USFDA inspection with zero observations

Indoco Remedies Limited, a leading Indian pharmaceutical company, announced today that its Active Pharmaceutical Ingredients (API) manufacturing facility at Patalganga, Navi Mumbai, has successfully p...

5 months ago - Business Upturn

Why are Indoco Remedies shares up 2% today? Explained

Indoco Remedies Ltd shares climbed over 2% to ₹299.30 in morning trade on Tuesday after the company announced it has received final approval from the US Food and Drug Administration (USFDA) for its Ab...

6 months ago - Business Upturn

Indoco Remedies gets USFDA nod for generic Rivaroxaban tablets; eyes growth in US Market

Mumbai-based Indoco Remedies Ltd. has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market Rivaroxaban Tablets USP in stren...

6 months ago - Business Upturn

Indoco Remedies signs Sale and Leaseback Agreemen for Waluj facility assets

Indoco Remedies Limited has announced a strategic move involving the sale and leaseback of some of its movable assets at its Waluj Facility in Aurangabad, Maharashtra. In a regulatory filing, the comp...

7 months ago - Business Upturn

Indoco Remedies launches Ticagrelor tablets in UK through subsidiary

Indoco Remedies Limited has officially launched its Ticagrelor film-coated tablets (90mg) in the United Kingdom through its subsidiary, Indoco Remedies UK Limited, on June 2, 2025. This marks a signif...

9 months ago - Business Upturn

Indoco Remedies receives USFDA approval for Generic Allopurinol Tablets USP 200 mg

Indoco Remedies Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Allopurinol Tablets USP 200 mg. The ...

9 months ago - Business Upturn

Indoco Remedies Q3 FY25 Results: Revenue declines 6.2% YoY to Rs 410.55 crore; Net loss widens to Rs 28.40 crore

Indoco Remedies Limited released its financial results for the quarter ending December 31, 2024 (Q3 FY25), reporting a decline in revenue and a net loss due to increased expenses and operational chall...

1 year ago - Business Upturn

Indoco Remedies shares plunge over 7% as Goa facility receives USFDA warning letter

Indoco Remedies’ shares fell sharply by 7.52% today following a significant setback, as the company’s Goa facility, contributing 65-70% of its revenue, received a warning letter from the USFDA. The wa...

1 year ago - Business Upturn

Indoco Remedies receives USFDA warning letter for Goa facility

Indoco Remedies has received a warning letter from the USFDA for its Goa facility, following an inspection conducted from July 16-26, 2024. This follows the earlier notification on October 11, 2024, w...

1 year ago - Business Upturn

Indoco Remedies stock surges 8% on partnership with Clarity Pharma in the UK

Indoco Remedies witnessed a significant 8% jump in its stock price following the announcement of a strategic distribution partnership with Clarity Pharma, UK. This collaboration is set to launch appro...

1 year ago - Business Upturn

Indoco Remedies partners with Clarity Pharma to strengthen UK presence

The partnership combines Indoco’s robust portfolio of high-quality, affordable pharmaceutical products with Clarity Pharma’s extensive distribution network and market expertise.

1 year ago - Business Upturn